NZ336898A - Sulfonamides for treatment of endothelin-mediated disorders - Google Patents

Sulfonamides for treatment of endothelin-mediated disorders

Info

Publication number
NZ336898A
NZ336898A NZ336898A NZ33689898A NZ336898A NZ 336898 A NZ336898 A NZ 336898A NZ 336898 A NZ336898 A NZ 336898A NZ 33689898 A NZ33689898 A NZ 33689898A NZ 336898 A NZ336898 A NZ 336898A
Authority
NZ
New Zealand
Prior art keywords
methyl
isoxazolyl
chloro
amino
sulfonyl
Prior art date
Application number
NZ336898A
Other languages
English (en)
Inventor
Chengde Wu
Natalie Blok
Timothy P Kogan
Karin Keller
Patricia Woodard
Original Assignee
Texas Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/847,797 external-priority patent/US5783705A/en
Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp
Publication of NZ336898A publication Critical patent/NZ336898A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NZ336898A 1997-04-28 1998-04-02 Sulfonamides for treatment of endothelin-mediated disorders NZ336898A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/847,797 US5783705A (en) 1997-04-28 1997-04-28 Process of preparing alkali metal salys of hydrophobic sulfonamides
US08/938,444 US6248767B1 (en) 1997-04-28 1997-09-26 Formulation of sulfonamides for treatment of endothelin-mediated disorders
PCT/US1998/006680 WO1998049162A1 (fr) 1997-04-28 1998-04-02 Sulfamides pour le traitement des troubles induits par l'endotheline

Publications (1)

Publication Number Publication Date
NZ336898A true NZ336898A (en) 2001-10-26

Family

ID=27126732

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ336898A NZ336898A (en) 1997-04-28 1998-04-02 Sulfonamides for treatment of endothelin-mediated disorders

Country Status (26)

Country Link
US (3) US6432994B1 (fr)
EP (1) EP0980369B1 (fr)
JP (3) JP3455233B2 (fr)
CN (2) CN1636994B (fr)
AP (1) AP9901643A0 (fr)
AT (1) ATE292129T1 (fr)
AU (1) AU749167B2 (fr)
BR (1) BR9812258A (fr)
CA (2) CA2496680A1 (fr)
CZ (1) CZ301452B6 (fr)
DE (2) DE69829558T2 (fr)
EA (1) EA003993B1 (fr)
EE (1) EE04156B1 (fr)
ES (1) ES2241133T3 (fr)
HK (1) HK1028033A1 (fr)
HU (1) HU227183B1 (fr)
ID (1) ID25921A (fr)
IL (2) IL156977A (fr)
NO (1) NO995221L (fr)
NZ (1) NZ336898A (fr)
OA (1) OA11167A (fr)
PL (1) PL197843B1 (fr)
SG (2) SG100767A1 (fr)
SK (1) SK143399A3 (fr)
TR (3) TR199902401T2 (fr)
WO (1) WO1998049162A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JP3050424B2 (ja) * 1991-07-12 2000-06-12 塩野義製薬株式会社 ヒトエンドセリンリセプター
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
DE69829558T2 (de) * 1997-04-28 2006-02-16 Encysive Pharmaceuticals Inc., Bellaire Sulfonamide für die behandlung von störungen durch endothelin vermittelt
EP1023269A4 (fr) * 1997-09-30 2001-06-27 Molecular Design Int Agonistes de beta3-adrenorecepteurs, compositions d'agonistes et procedes d'utilisation
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
ES2236028T3 (es) * 1999-12-31 2005-07-16 Encysive Pharmaceuticals, Inc Sulfonamidas y sus derivados que modulan la actividad de la endotelina.
EP1533311B1 (fr) * 1999-12-31 2007-04-25 Encysive Pharmaceuticals, Inc Sulfonamide et leurs dérivés comme modulateurs de l'activité de l'endothélin.
WO2001049289A1 (fr) * 1999-12-31 2001-07-12 Texas Biotechnology Corporation Utilisations pharmaceutiques et veterinaires d'antagonistes de l'endotheline et applications associees
US6593341B2 (en) 2001-03-29 2003-07-15 Molecular Design International, Inc. β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
AU2002344854B2 (en) * 2001-06-11 2008-11-06 Vertex Pharmaceuticals (Canada) Incorporated Thiophene derivatives as antiviral agents for flavivirus infection
AU2003210811B2 (en) * 2002-01-30 2008-08-14 Amgen Inc. Arylsulfonamidobenzylic compounds
US6596734B1 (en) 2002-10-11 2003-07-22 Molecular Design International, Inc. Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
ES2345438T3 (es) 2002-12-10 2010-09-23 Virochem Pharma Inc. Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
US7754831B2 (en) * 2002-12-25 2010-07-13 Mitsubishi Rayon Co., Ltd. Vinyl polymer, process for producing vinyl polymer, thermosetting coating composition, and coating material
US20060011305A1 (en) * 2003-09-19 2006-01-19 Donald Sandell Automated seal applicator
US7871632B2 (en) * 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
AU2011205048B2 (en) * 2005-05-13 2013-05-02 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
SG161315A1 (en) * 2005-05-13 2010-05-27 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070219825A1 (en) * 2005-11-23 2007-09-20 Maetzold Derek J Method of managing and reducing side effects associated with exposure to a drug
MX2008011227A (es) * 2006-03-03 2009-02-10 Torrent Pharmaceuticals Ltd Receptores antagonistas de accion nueva y doble en los receptores at1 y eta.
AU2007225207A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Formulations of sitaxsentan sodium
EP1996162A2 (fr) * 2006-03-13 2008-12-03 Encysive Pharmaceuticals, Inc Procedes et compositions pour le traitement d'une insuffisance cardiaque diastolique
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
PL2104674T3 (pl) 2006-11-15 2013-12-31 Vertex Pharmaceuticals Canada Incorporated Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym
ES2340640T3 (es) 2007-03-23 2010-06-07 Icagen, Inc. Inhibidores de canales de iones.
JP2009026126A (ja) * 2007-07-20 2009-02-05 Nec Electronics Corp 半導体装置
DK2209501T3 (da) * 2007-10-12 2012-02-27 Astrazeneca Ab Zibotentan-sammensætning, der indeholder mannitol og mikrokrystallinsk cellulose
EP2511263A1 (fr) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Composés de pyrrolo sulfonamide pour la modulation d'activité de récepteur-gamma orphelin (gamme ROR, NR1F3) associée au RAR de récepteur nucléaire orphelin et pour le traitement des maladies inflammatoires et de maladies auto-immunes chroniques
US20180187263A1 (en) 2017-01-05 2018-07-05 Iowa State University Research Foundation, Inc. Kits for diagnostic detection and prevention of feedlot bovine respiratory disease
CN106831736A (zh) * 2017-02-15 2017-06-13 浙江华海药业股份有限公司 一种制备帕罗西汀杂质的方法
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
ES2969616T3 (es) 2019-06-18 2024-05-21 Pfizer Derivados de benzisoxazol sulfonamida
EP4308554A1 (fr) * 2021-03-15 2024-01-24 The Board of Trustees of the University of Illinois Composés, compositions et méthodes de traitement du diabète de type 2 et de la démence
AU2022297082B2 (en) 2021-06-22 2024-04-18 Alchemedicine, Inc. Compound, endothelin A receptor antagonist and pharmaceutical composition

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB804036A (en) 1956-03-02 1958-11-05 Hoffmann La Roche A process for the manufacture of a sulphanilamide of the isoxazole series
US2888455A (en) 1956-09-04 1959-05-26 Shionogi & Co New sulfonamide and process for producing the same
US3225085A (en) 1961-09-15 1965-12-21 Monsanto Co Succinic acid derivatives
US3300488A (en) 1963-12-23 1967-01-24 Shionogi & Co Nu, nu'-bis [4-halogenated-5-alkyl-3-isoxazolylsulfamoyl)-phenyl]-ureas
FR1404615A (fr) 1964-05-22 1965-07-02 Kuhlmann Ets Nouveaux colorants pour fibres à base de polyesters
NL128672C (fr) 1964-08-08
US3660383A (en) 1968-08-14 1972-05-02 Shionogi & Co Production of iodoisoxazole compounds
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
GB1473433A (fr) 1975-10-09 1977-05-11 Banyu Pharmaceutical Co Ltd Hi
US4315014A (en) 1980-09-24 1982-02-09 Warner-Lambert Company Antibacterial amide compounds and pharmaceutical composition containing the same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
DE3276313D1 (en) 1981-09-24 1987-06-19 Beecham Wuelfing Gmbh & Co Kg Sulphonamides
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0194548A3 (fr) 1985-03-12 1988-08-17 Dr. Karl Thomae GmbH Composés sulfonylaminoéthyl, médicament contenant ces composés et leur procédé de préparation
US4914112A (en) 1986-06-03 1990-04-03 Sumitomo Pharmaceuticals Company, Limited Aminoazole derivatives and their production and use
DE3735555A1 (de) * 1987-03-07 1988-09-15 Bayer Ag Aminomethylheterocyclen
NZ225307A (en) * 1987-07-10 1991-06-25 Hoffmann La Roche Heterocyclic containing alkene derivatives and pharmaceutical compositions
US4752613A (en) 1987-08-03 1988-06-21 E. R. Squibb & Sons, Inc. Sulphonamidothienylcarboxylic acid compounds
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5112866A (en) * 1988-09-06 1992-05-12 Ortho Pharmaceutical Corporation Ethanesulfonamide derivatives
US4997836A (en) 1988-11-11 1991-03-05 Takeda Chemical Industries, Ltd. Trisubstituted piperazine compounds, their production and use
DK0411150T3 (da) 1989-02-10 1996-12-16 Otsuka Pharma Co Ltd Indolderivater
US5082838A (en) 1989-06-21 1992-01-21 Takeda Chemical Industries, Ltd. Sulfur-containing fused pyrimidine derivatives, their production and use
JPH0347163A (ja) 1989-06-30 1991-02-28 Fujisawa Pharmaceut Co Ltd アントラキノン誘導体およびその製造
US5230999A (en) 1989-07-24 1993-07-27 Takeda Chemical Industries, Ltd. Monoclonal antibody to endothelin-3 or precursor thereof and use thereof
CA2032559C (fr) 1989-12-28 2001-11-06 Kiyofumi Ishikawa Pentapeptides cycliques antagonistes de l'endotheline
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
CA2043741C (fr) 1990-06-07 2003-04-01 Kiyofumi Ishikawa Derives de peptides antagonistes d'endotheline
CA2056142A1 (fr) 1990-11-27 1992-05-28 Hirotomo Masuya Composes a base de pyridopyridazine et leur utilisation
CA2059380A1 (fr) 1991-01-24 1992-07-25 Yiu-Kuen T. Lam Antagonistes d'un recepteur d'endotheline, isoles a partir de microbispora
DE69129193T2 (de) 1991-01-29 1998-07-30 Shionogi Seiyaku K K Trading U Triterpenderivat
CA2061246A1 (fr) 1991-02-15 1992-08-16 Mitsuhiro Wakimasu Peptides, leur production et leur utilisation
TW270116B (fr) 1991-04-25 1996-02-11 Hoffmann La Roche
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
FR2679906B1 (fr) 1991-07-31 1995-01-20 Adir Nouvelles (isoquinolein-5 yl) sulfonamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB2259450A (en) 1991-09-11 1993-03-17 Fujisawa Pharmaceutical Co Compositions with endothelin antagonist activity
US5198548A (en) 1992-01-30 1993-03-30 Warner-Lambert Company Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof
FR2687675B1 (fr) 1992-01-31 1997-04-18 Roussel Uclaf Nouveaux derives bicycliques de la pyridine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
US5378715A (en) 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
TW224462B (fr) * 1992-02-24 1994-06-01 Squibb & Sons Inc
LT3200B (en) 1992-03-18 1995-03-27 Takeda Chemical Industries Ltd Triazolopyridazine methodfor production thereof and use
US5240910A (en) 1992-04-17 1993-08-31 Merck & Co., Inc. Antihypertensive compounds produced by fermentation
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
WO1993023404A1 (fr) 1992-05-19 1993-11-25 Immunopharmaceutics, Inc. Composes modulant l'activite de l'endotheline
ES2042421B1 (es) 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
TW287160B (fr) 1992-12-10 1996-10-01 Hoffmann La Roche
US5420123A (en) 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists
US5352800A (en) 1993-03-11 1994-10-04 Merck & Co., Inc. Process for the production of a novel endothelin antagonist
US5420133A (en) 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5565485A (en) 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5334598A (en) 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
ES2062943B1 (es) 1993-03-23 1995-11-16 Uriach & Cia Sa J Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
CA2121724A1 (fr) 1993-04-21 1994-10-22 Toshifumi Watanabe Methodes et compositions pour la prophylaxie et/ou le traitement de l'hypofonction organique
US6030991A (en) 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
FR2707089B1 (fr) 1993-06-30 1995-08-18 Adir Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5389620A (en) 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
HUT74179A (en) 1993-08-19 1996-11-28 Warner Lambert Co Substituted 2(5h)furanone, 2(5h)thiophenone and 2(5h)pyrrolone derivatives, their preparation and their use as endothelin antagonists
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
IL111959A (en) 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
JP3328045B2 (ja) 1994-02-08 2002-09-24 日清製粉株式会社 粉体サンプル調整装置
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE4440066A1 (de) 1994-11-10 1996-05-15 Basf Ag Methin- und Azamethinfarbstoffe auf Basis von Trifluormethylpyridonen
ATE223899T1 (de) 1994-12-20 2002-09-15 Hoffmann La Roche Aryl-und hetaryl-sulfonamid derivate, deren herstellung und deren verwendung als endothelin- antagonisten
CA2168154A1 (fr) 1995-02-06 1996-08-07 Natesan Murugesan Derives de substitution biphenyliques de sulfonamide, antagonistes de l'endotheline
US5599811A (en) 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
DE19509950A1 (de) 1995-03-18 1996-09-19 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
CA2217169C (fr) * 1995-04-04 2005-03-29 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- et biphenyl sulfonamides et leurs derives modulant l'activite de l'endotheline
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5922759A (en) 1996-06-21 1999-07-13 Warner-Lambert Company Butenolide endothelin antagonists
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
DE69624262T2 (de) * 1995-11-17 2003-09-11 Warner Lambert Co Sulfonamidinhibitoren von matrix metalloproteinasen
RU2172735C2 (ru) 1995-12-20 2001-08-27 Яманоути Фармасьютикал Ко., Лтд. Арилэтенсульфонамидные производные и фармацевтическая композиция
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
DK0896533T3 (da) * 1996-02-22 2004-01-26 Tularik Inc Pentafluorbenzensulfonamider og analoger
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US6043241A (en) 1996-04-10 2000-03-28 Warner-Lambert Company Ketoacid endothelin antagonists
AU1991197A (en) 1996-04-10 1997-10-29 Warner-Lambert Company Endothelin antagonists with ether-linked groups
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
DE69829558T2 (de) * 1997-04-28 2006-02-16 Encysive Pharmaceuticals Inc., Bellaire Sulfonamide für die behandlung von störungen durch endothelin vermittelt
US6313119B1 (en) * 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6300341B1 (en) * 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
ES2236028T3 (es) 1999-12-31 2005-07-16 Encysive Pharmaceuticals, Inc Sulfonamidas y sus derivados que modulan la actividad de la endotelina.

Also Published As

Publication number Publication date
TR199902401T2 (xx) 2000-08-21
SK143399A3 (en) 2000-05-16
EA199900966A1 (ru) 2000-08-28
TR200202738T2 (tr) 2003-03-21
ES2241133T3 (es) 2005-10-16
ATE292129T1 (de) 2005-04-15
TR200101905T2 (tr) 2002-06-21
JP2001520643A (ja) 2001-10-30
US6432994B1 (en) 2002-08-13
US20010039289A1 (en) 2001-11-08
HU227183B1 (en) 2010-09-28
US6458805B2 (en) 2002-10-01
US6683103B2 (en) 2004-01-27
DE69839534D1 (de) 2008-07-03
EE04156B1 (et) 2003-10-15
JP4256150B2 (ja) 2009-04-22
CN1636994B (zh) 2010-05-12
IL156977A (en) 2005-03-20
HUP0001442A2 (hu) 2001-11-28
ID25921A (id) 2000-11-09
PL197843B1 (pl) 2008-05-30
EP0980369B1 (fr) 2005-03-30
IL131318A0 (en) 2001-01-28
CA2496680A1 (fr) 1998-11-05
SG100766A1 (en) 2003-12-26
SG100767A1 (en) 2003-12-26
CZ367599A3 (cs) 2000-02-16
CN1636994A (zh) 2005-07-13
HK1028033A1 (en) 2001-03-02
IL156977A0 (en) 2004-02-08
DE69829558T2 (de) 2006-02-16
CN1253560A (zh) 2000-05-17
JP3455233B2 (ja) 2003-10-14
AP9901643A0 (en) 1999-10-02
EE9900469A (et) 2000-06-15
NO995221D0 (no) 1999-10-26
CZ301452B6 (cs) 2010-03-10
HUP0001442A3 (en) 2001-12-28
CA2281090C (fr) 2005-06-07
PL336290A1 (en) 2000-06-19
NO995221L (no) 1999-12-28
CA2281090A1 (fr) 1998-11-05
DE69829558D1 (de) 2005-05-04
AU6950498A (en) 1998-11-24
US20020091270A1 (en) 2002-07-11
AU749167B2 (en) 2002-06-20
BR9812258A (pt) 2000-07-25
WO1998049162A1 (fr) 1998-11-05
EP0980369A1 (fr) 2000-02-23
IL131318A (en) 2004-08-31
EA003993B1 (ru) 2003-12-25
JP2008074875A (ja) 2008-04-03
JP2003176288A (ja) 2003-06-24
OA11167A (en) 2003-04-29
CN1179961C (zh) 2004-12-15

Similar Documents

Publication Publication Date Title
CA2281090C (fr) Composes de sulfamides et sels pour le traitement des troubles induits par l'endotheline
EP1498418B1 (fr) Sulphonamides pour le traitement des troubles induits par l'endothéline
EP0946552B1 (fr) Sulfonamides et derives de ceux-ci, modulant l'activite de l'endotheline
CA2395684C (fr) Sulfonamides et leurs derives modulant l'activite de l'endotheline
EP0819125A1 (fr) Thienyl-, furyl-, pyrrolyl- et biphenyl sulfonamides et leurs derives modulant l'activite de l'endotheline
EP1533311B1 (fr) Sulfonamide et leurs dérivés comme modulateurs de l'activité de l'endothélin.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)